5.01

1.38% -0.07

After Hours: 5.01

Wave Life Sciences Ltd. (WVE)

Overview News Price History Option Chain Why WVE Down? Discussions Forecast

Wave Life Sciences Ltd. stock is currently priced at $5.01, with a 24-hour trading volume of 421.95K. It has seen a -1.38% decreased in the last 24 hours and a -13.17% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $5.07 pivot point. If it approaches the $4.96 support level, significant changes may occur.

Previous Close:

$5.08

Open:

$5.05

24h Volume:

421.95K

Market Cap:

$612.64M

Revenue:

$113.31M

Net Income/Loss:

$-57.51M

P/E Ratio:

-3.6838

EPS:

-1.36

Net Cash Flow:

$-20.55M

1W Performance:

+4.59%

1M Performance:

-13.17%

6M Performance:

-10.38%

1Y Performance:

+24.63%

1D Range:

$4.96

$5.23

52W Range:

$3.1501

$7.67

Wave Life Sciences Ltd. Stock (WVE) Company Profile

Name

Wave Life Sciences Ltd.

Sector

Healthcare (1198)

Industry

Biotechnology (688)

Phone

Address

Marina One East Tower, No. 12-00, 7 Straits View, Singapore

Employee

168

Twitter

@WAVELifeSci

Next Earnings Date

2024-05-01

Latest SEC Filings

WVE's Discussions on Twitter

Wave Life Sciences Ltd. Stock (WVE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-05-23	Initiated	Raymond James	Outperform
May-24-23	Downgrade	Jefferies	Buy → Hold
Dec-15-20	Resumed	H.C. Wainwright	Buy
Oct-23-20	Initiated	RBC Capital Mkts	Sector Perform
Dec-31-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-01-19	Initiated	Guggenheim	Buy
Jul-15-19	Initiated	Cowen	Market Perform
Apr-17-19	Reiterated	H.C. Wainwright	Buy
Aug-07-18	Initiated	Stifel	Buy
Jul-23-18	Initiated	H.C. Wainwright	Buy
Mar-19-18	Reiterated	Mizuho	Buy
Feb-15-17	Initiated	H.C. Wainwright	Buy
Nov-10-16	Resumed	Leerink Partners	Outperform
Dec-07-15	Initiated	JMP Securities	Mkt Outperform
Dec-07-15	Initiated	Jefferies	Buy
Dec-07-15	Initiated	Leerink Partners	Outperform
Dec-07-15	Initiated	Sun Trust Rbsn Humphrey	Buy

View All

Wave Life Sciences Ltd. Stock (WVE) Latest News

Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday

Benzinga

Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire Inc.

Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024

GlobeNewswire Inc.

Wave Life Sciences (WVE) Surges 10.9%: Is This an Indication of Further Gains?

Zacks Investment Research

Wave Life Sciences Ltd. Stock (WVE) Financials Data

Wave Life Sciences Ltd. (WVE) Revenue 2024

WVE reported a revenue (TTM) of $113.31 million for the quarter ending December 31, 2023, a +3,005% rise year-over-year.

Wave Life Sciences Ltd. (WVE) Net Income 2024

WVE net income (TTM) was -$57.51 million for the quarter ending December 31, 2023, a +64.46% increase year-over-year.

Wave Life Sciences Ltd. (WVE) Cash Flow 2024

WVE recorded a free cash flow (TTM) of -$20.55 million for the quarter ending December 31, 2023, a +84.09% increase year-over-year.

Wave Life Sciences Ltd. (WVE) Earnings per Share 2024

WVE earnings per share (TTM) was -$0.55 for the quarter ending December 31, 2023, a +74.18% growth year-over-year.

Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics, as well as a collaboration agreement with Deep Genomics Inc. for identifying novel therapies. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.